3:05 PM
 | 
Dec 06, 2017
 |  BC Extra  |  Company News

Juno licenses gamma secretase inhibitor, related IP

Juno Therapeutics Inc. (NASDAQ:JUNO) announced on Wednesday a trio of licensing agreements to advance its multiple myeloma (MM) program combining gamma secretase inhibitors and tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17; CD269)-directed chimeric antigen receptor (CAR) T cells.

Under a deal with Eli Lilly and Co. (NYSE:LLY), Juno...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >